BIOMODA INC
			Symbol			BMOD

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Biomoda Awarded New Patent

2009-11-03 14:15 ET - News Release

Biomoda’s Patent Portfolio Continues to Expand

ALBUQUERQUE, N.M. -- (Business Wire)

Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda’s screening assay for the early detection of cancer.

The U.S. Patent entitled “Method for Making 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) Solution and Composition Comprising TCPP,” describes the new formulation of the Biomoda assay trademarked under the name CyPath®.

“This patent basically gives Biomoda a lock on the ‘recipe’ for the TCPP Labeling Solution," said Biomoda President John Cousins. "Our formulation moves beyond the original work done on TCPP at Los Alamos National Laboratory and incorporates the cutting-edge science we are doing in our own lab.”

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.